Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Declines By 18.2%

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 4,870,000 shares, a drop of 18.2% from the April 30th total of 5,950,000 shares. Based on an average trading volume of 899,100 shares, the days-to-cover ratio is presently 5.4 days.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Corton Capital Inc. purchased a new position in Aclaris Therapeutics during the third quarter valued at $102,000. Vontobel Holding Ltd. raised its stake in Aclaris Therapeutics by 128.8% during the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 17,040 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aclaris Therapeutics during the first quarter valued at $39,000. SG Americas Securities LLC raised its stake in Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 13,461 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Aclaris Therapeutics by 115.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 23,467 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.25.

View Our Latest Report on Aclaris Therapeutics

Aclaris Therapeutics Stock Performance

NASDAQ ACRS opened at $1.03 on Friday. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $11.12. The stock has a 50 day simple moving average of $1.20 and a two-hundred day simple moving average of $1.14. The stock has a market cap of $73.40 million, a P/E ratio of -0.94 and a beta of 0.23.

Aclaris Therapeutics (NASDAQ:ACRSGet Free Report) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. Sell-side analysts predict that Aclaris Therapeutics will post -0.81 earnings per share for the current year.

Aclaris Therapeutics Company Profile

(Get Free Report)

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

Recommended Stories

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.